INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial

Hatz Katja; Prunte Christian

首页> 外文期刊>Retina >INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial

【24h】

INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial

机译：玻璃体内术语AfliBercept在新生血管年龄相关的黄斑变性，其对Ranibizumab A的有限反应进行治疗和延伸试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To evaluate aflibercept treat-and-extend regimen for treatment of neovascular age-related macular degeneration in patients with limited response to ranibizumab.

机译：目的：评价Aflibercept治疗和延伸方案，用于治疗患者对Ranibizumab有限患者的新生血管年龄相关性黄斑变性。

著录项

来源
《Retina》 |2017年第6期|共8页
作者
Hatz Katja; Prunte Christian;
展开▼
作者单位

Vista Klin Dept Ophthalmol Binningen Switzerland;

Vista Klin Dept Ophthalmol Binningen Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词
aflibercept; ranibizumab; treat-and-extend; anti-VEGF; neovascular age-related macular degeneration;

机译：AfliBelcept;Ranibizumab;治疗和延伸;抗VEGF;新生血管年龄相关的黄斑变性;

相似文献

外文文献
中文文献
专利

1. INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial [J] . Hatz Katja, Prunte Christian Retina . 2017,第6期

机译：玻璃体内术语AfliBercept在新生血管年龄相关的黄斑变性，其对Ranibizumab A的有限反应进行治疗和延伸试验
2. Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results' [J] . Homer N., Grewal D. S., Mirza R. G., Eye . 2015,第12期

机译：对以下问题的回复：“关于在新血管性年龄相关性黄斑变性中采用既往治疗和延长剂量方案后过渡到玻璃体内阿柏西普的评论：24个月的结果”
3. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials [J] . Khurana Rahul N., Rahimy Ehsan, Joseph W. Anthony, American Journal of Ophthalmology: The International Journal of Ophthalmology . 2019,第期

机译：延长（每12周或更长时间）给药间隔，具有玻璃体腹部Aflibercept和Ranibizumab在新生血管年龄相关的黄斑变性：观测试验后的HOC分析
4. Expression Pattern of Kinin-Dependent Genes in Peripheral Blood Mononuclear Cells After Age-Related Macular Degeneration Treatment with Ranibizumab [C] . Michalska-Malecka K, Strzalka-Mrozik B., Kimsa M.W., International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：与RANIBIZIMAB的年龄相关黄斑治疗后外周血单核细胞在外周血单核细胞中的表达模式
5. Characterizing response patterns to ranibizumab therapy in patients with wet age-related macular degeneration: A latent class growth analysis [D] . Sun, Diana 2015

机译：潮湿年龄相关性黄斑变性患者的ranibizumab治疗的表征反应模式：潜在的增长分析
6. Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results [O] . N Homer, D S Grewal, R G Mirza, 2015

机译：对以下问题的回应：关于在新血管性年龄相关性黄斑变性中采用既往治疗和延长剂量方案后过渡至玻璃体内阿柏西普的评论：24个月的结果
7. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials [O] . Rahul N. Khurana, Ehsan Rahimy, W. Anthony Joseph, 2019

机译：延长（每12周或更长时间）给药间隔，具有玻璃体肌钙术和ranibizumab在新生血管年龄相关的黄斑变性：观察试验后的HOC分析

INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial

摘要

著录项

相似文献

相关主题

期刊订阅